Article contents
Tap any item to jump directly to the section you need.
Missing teeth can affect more than just appearance. They can compromise chewing function, oral health, and overall quality of life. Dental implants are widely recognized as a reliable long-term solution for tooth replacement, yet many patients remain concerned about complex surgical procedures, bone grafting, and lengthy treatment times.
Straumann® Roxolid® was developed to help address these concerns by offering a less invasive treatment approach for many patients, particularly those with limited bone availability.
What Is Roxolid®?
Roxolid® is Straumann’s proprietary titanium-zirconium alloy, consisting of 85% titanium and 15% zirconium. This unique combination creates a material with higher mechanical strength than pure titanium while maintaining excellent osseointegration properties.
Because of its enhanced strength, Roxolid® enables the use of smaller-diameter implants in many clinical situations.
Potentially Avoiding Bone Grafting Procedures
One of the main reasons patients hesitate to undergo implant treatment is the possibility of bone augmentation surgery.
According to Straumann, reduced-diameter Roxolid® implants can expand treatment options for patients with narrow spaces or limited bone availability. In many suitable cases, this may help avoid more invasive bone grafting procedures.
Potential benefits include:
Less invasive treatment
Reduced patient anxiety
Simplified treatment planning
Greater acceptance of implant therapy
A More Comfortable Treatment Experience
The increased strength of Roxolid® allows clinicians to use smaller and shorter implants in appropriate cases.
This may provide several patient-centered advantages:
Reduced drilling requirements
Preservation of anatomical structures
Less post-operative discomfort
Improved treatment comfort
Straumann has also introduced the Roxolid® 4 mm Extra-short Implant, offering additional treatment possibilities for patients with limited vertical bone height.
Stronger Than Conventional Titanium
Mechanical testing has demonstrated that Roxolid® provides higher tensile strength than conventional Grade 4 titanium. This enhanced performance enables the development of smaller implants without compromising strength.
Straumann reports an accumulated fracture rate of only 0.04% for Roxolid® implants, highlighting the material’s long-term reliability.
Supported by Long-Term Clinical Evidence
Long-term clinical performance is a key consideration for anyone choosing dental implant treatment.
Straumann clinical data demonstrate 10-year follow-up results for Roxolid® implants, showing an implant survival rate of 98.9% while maintaining stable bone levels comparable to titanium implants.
These findings support Roxolid® as a clinically validated solution designed for predictable long-term outcomes.
A Modern Approach to Implant Treatment
For patients seeking a trusted implant solution, Straumann® Roxolid® offers a combination of advanced material science, treatment flexibility, and long-term clinical validation.
By enabling less invasive treatment approaches in many suitable cases, Roxolid® may help more patients benefit from implant therapy while maintaining comfort, confidence, and long-term stability. Consult your dental professional to determine whether Roxolid® is the right option for your individual needs.